0A23 Stock Chart & Stats
$28.50
$0.00(0.00%)
At close: 4:00 PM EDT
$28.50
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$28.50 - $28.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$679.06M
Enterprise Value$665.23
Total Cash (Recent Filing)$72.94M
Total Debt (Recent Filing)$61.84M
Price to Earnings (P/E)63.5
Beta0.64
Next Earnings
Dec 09, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding62,070,946
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-3.35
Price to Book (P/B)2.38
Price to Sales (P/S)1.67
P/FCF Ratio11.85
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$13.44Price Target Upside-52.83% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.4
Revenue Forecast (FY)$514.95M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong and rising operating and free cash flow indicate that Phreesia is increasingly converting its platform revenues into internally generated funding. This supports debt reduction, product investment, and continued execution without relying as heavily on external capital.
Profitability InflectionThe shift from substantial historical losses to positive net income and EBIT marks an important improvement in the business model. Even though margins remain modest, continued operating leverage could make earnings more durable as revenue expands across the platform.
Expanding Customer BaseGrowth in both the customer base and revenue per healthcare services client suggests Phreesia is expanding its provider footprint while increasing monetization within that network. This combination supports recurring platform growth and creates a foundation for additional module adoption.
Bears Say
Thin Profitability CushionAlthough profitability has turned positive, the narrow margin leaves limited protection if growth slows or operating costs rise. A small deterioration in execution could therefore materially reduce earnings, making sustained cost discipline and operating leverage important.
Provider Economic PressureFinancial pressure among healthcare providers can make customers more cautious about technology spending and slow expansion across locations or modules. It may also lengthen sales decisions and require Phreesia to demonstrate clear economic value to preserve growth.
Pricing ModerationModerating subscription pricing may support customer retention and broader network adoption, but it can constrain near-term revenue per client and margin expansion. The strategy depends on downstream payments and network growth offsetting lower direct pricing.
Phreesia News
0A23 FAQ
What was Phreesia’s price range in the past 12 months?
Phreesia lowest share price was $28.50 and its highest was $28.50 in the past 12 months.
What is Phreesia’s market cap?
Phreesia’s market cap is $679.06M.
When is Phreesia’s upcoming earnings report date?
Phreesia’s upcoming earnings report date is Dec 09, 2026 which is in 93 days.
How were Phreesia’s earnings last quarter?
Phreesia released its earnings results on Sep 02, 2026. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.085 by -$0.055.
Is Phreesia overvalued?
According to Wall Street analysts Phreesia’s price is currently Overvalued.
Does Phreesia pay dividends?
Phreesia does not currently pay dividends.
What is Phreesia’s EPS estimate?
Phreesia’s EPS estimate is 0.13.
How many shares outstanding does Phreesia have?
Phreesia has 62,070,946 shares outstanding.
What happened to Phreesia’s price movement after its last earnings report?
Phreesia reported an EPS of $0.03 in its last earnings report, missing expectations of $0.085. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Phreesia?
Currently, no hedge funds are holding shares in GB:0A23
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phreesia Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.44 (-52.83% Downside)
$13.44 (-52.83% Downside)
Blogger Sentiment
Neutral
GB:0A23 Sentiment 75%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 12%
Bearish news 12%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
58.33%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Phreesia
Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.
0A23 Company Deck
0A23 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly constructive, with 10% year-over-year revenue growth, substantial adjusted EBITDA expansion, positive net income for the fifth consecutive quarter, continued positive cash flow, more than $23 million of debt reduction, and reaffirmed fiscal 2027 guidance. AccessOne, Provider Connect, the GLP-1 campaign, and AI initiatives showed encouraging momentum. The main challenges were sequential declines tied to payment-processing seasonality, provider economic strain, pricing moderation, and some earlier volume weakness beyond seasonality.View all GB:0A23 earnings summaries0A23 Revenue Breakdown
45.91% Subscription and related services
27.90% Payment processing fees
26.19% Network solutions
0A23 Stock 12 Month Forecast
Average Price Target
$13.44
▼(-52.83% Downside)
Technical Analysis
CareCloud
―
Evolent Health
―
Health Catalyst
―
American Well
―
Waystar Holding Corp.
―